Milnubes / Curiosity, with sourcesBotany · Culture · Science
Cannabinoid atlas / Reference entry
CBT
Plant cannabinoids

Cannabitriol and the ambiguity of CBT

Before assigning properties to CBT, establish which full name the letters stand for. This profile starts with cannabitriol; it also explains why a search may return cannabicitran, a different molecule whose findings must not be mixed with those for cannabitriol.

Collection of leaves in different shapes and colours arranged on white.
Leaf diversity in a stock composition. The image does not identify cannabis or establish cannabinoid content in these plants.
Evidence map

Laboratory or animals. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.

How we read studies and personal accounts ↗

Identity

CBT can mean cannabitriol or cannabicitran: they are different molecules.

Terms associated with this entry: cannabitriol.

Two conflicting naming conventions

A 2025 study distinguishes CBT (cannabitriol) from CBCT (cannabicitran); a 2022 paper calls cannabicitran CBT.

What can be said about each

Cannabitriol was studied in rat neurons, not patients.

The other molecule is not a spelling detail

A 2023 study isolated the two enantiomeric forms of cannabicitran and found a racemic mixture. It left explanations involving formation in the plant or during processing open; it did not establish a single origin.

When reading a product information sheet or article, establish that full identity first. Only then can you discuss which experiment applies and what it measured. When the name is missing, adding adjectives or references cannot fix the underlying problem: the texts may concern different substances.

What has been studied

Risks and gaps

Documented forms

Identity requires clarificationAn abbreviation alone does not identify a documented formulation.

A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.

Experiences

We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.

Conclusion

The first useful conclusion about CBT concerns naming. No benefit, risk or personal account should be transferred between these molecules merely because they share three letters.

Legal context

Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.

Sources

  1. Modulatory Effects of “Minor” Cannabinoids in an in vitro Model of Neuronal Hypersensitivity · Laboratory study
  2. Inhibitory Effects of Cannabinoids on Acetylcholinesterase and Butyrylcholinesterase Enzyme Activities · Laboratory study
  3. Cannabicitran: Its unexpected racemic nature and potential origins · Original research

Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.